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Vascular Development
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Alterations in the ocular vasculature are associated with retinal diseases such as retinopathy of prematurity and diabetic
retinopathy. Vascular endothelial growth factor (VEGF) as a potent stimulator for normal and abnormal vascular growth has
been extensively studied. However, little is known about secreted factors that negatively regulate vascular growth in ocular
tissues. We now report that expression of a self-activating TGFb1 in the ocular lens of transgenic mice results in inhibition
f retinal angiogenesis followed by retinal degeneration. Transgenic TGFb1 can rescue the hyperplasic hyaloid tissue and
reverse the corneal deficiency in TGFb2-null embryos. These results demonstrate that TGFb signaling modulates
evelopment of ocular vasculature and cornea in a dosage-dependent manner and that TGFb1 can substitute for TGFb2 in
cular tissues. © 2001 Academic Press






Neovascularization in the eye causes severe visual im-
pairment in a number of diseases, including retinopathy of
prematurity, diabetic retinopathy, and the wet form of
age-related macular degeneration (Campochiaro, 2000). It
has been proposed that normal or abnormal growth of blood
vessels in the retina is driven by hypoxia and/or hypogly-
cemia (Stone and Maslim, 1997). The proliferative effect of
hypoxia/hypoglycemia on vascular endothelial cells is
thought to be mediated by VEGF (Stone and Maslim, 1997).
However, whether there are secreted proteins in the eye
that can counterbalance the effects of VEGF and modulate
ocular angiogenesis remains unknown. Identification of
such negative regulators could have implications for treat-
ment of ocular diseases caused by abnormal angiogenesis.
Members of the transforming growth factor family
(TGFb1, TGFb2, and TGFb3) are multifunctional proteins
hat regulate cell growth, differentiation, migration, and
xtracellular matrix production and play important roles in
mbryonic development, wound healing, immune re-
ponses, and vascular development (Massague, 1998;
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s high-molecular-weight latent complexes in which
-terminal mature homodimers are associated with inhibi-
ory dimers of the N-terminal pro-region (known as the
atency-associated peptide) (Khalil, 1999). Abnormalities in
GFb function cause or contribute to a number of human
diseases, including fibrosis, cancer, hereditary hemorrhagic
telangiectasia, atherosclerosis, and various developmental
defects (Blobe et al., 2000). Animal studies have shown that
TGFb can be either angiogenic or anti-angiogenic. TGFb
can be a potent inducer of angiogenesis when administered
subcutaneously to mice or rats (Roberts et al., 1986; Sprugel
et al., 1987; Rubbia-Brandt et al., 1991; Frank et al., 1994),
when applied to the chick chorioallantoic membrane (Yang
and Moses, 1990) or the rabbit cornea (Phillips et al., 1992,
1993), or in the disc angiogenesis system (Fajardo et al.,
1996). In contrast to the above findings, TGFb1 has been
shown to inhibit vascular tumor growth (Dong et al., 1996)
and FGF-induced angiogenesis (Passaniti et al., 1992).
Tissue-specific overexpression of TGFb in transgenic mice
does not induce angiogenesis (Nabel et al., 1993; Jhappan et
al., 1993; Pierce et al., 1993; Lee et al., 1995; Sanderson et
al., 1995; Wyss-Coray et al., 1995; Sellheyer et al., 1995;
Zhou et al., 1996). It has been shown that all three members
of the TGFb family and their type I and II receptors are
expressed in developing and adult rodent eyes (Srinivasan et
al., 1998; Gordon-Thomson et al., 1998; Obata et al., 1999).
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46 Zhao and OverbeekFIG. 1. Lens-specific transgene expression. An RNA probe specific to the transgenic SV40 sequences was hybridized to E16 embryonic eye
sections from the wild-type (A, E) and transgenic families, OVE853 (B, F), OVE917 (C, G), and OVE920A (D, H). The upper panels are
bright-field images (A–D) and the lower panels are dark-field images (E–H). Family OVE920A shows the highest levels of transgene
expression. Transgene expression in all families is confined to the elongated fiber cells of the lens. The cornea in the OVE920A embryo is
2- to 3-fold thicker than in the wild-type embryo while the corneal thickness in families OVE853 or OVE917 is comparable to the wild type.
Scale bars, 100 mm. Abbreviations: C, cornea; L, lens; NR, neural retina.
FIG. 2. Retinal degeneration in TGFb1 transgenic mice (FVB/N 3 C57BL/6). In 3-week-old and 1-month-old wild-type mice (A, D), retinal
differentiation was complete and three distinct nuclear layers can be clearly seen. In 3-week-old OVE920A transgenic mice (B, C), the retina
remained attached to the lens and was significant thinner than the wild type. (B, C) Two different regions in the same retinal section. Severe
photoreceptor degeneration was often associated with loss of RPE pigmentation and choroid tissues (arrow in C). At 1 month of age,
reduction in retinal thickness became apparent in family OVE917 (E). By 3 months of age, significant loss of ganglion and inner nuclear layer
cells was apparent in certain regions of the retina in this family (F). TUNEL assays on 3-week-old OVE920A mouse retina show no apoptotic
cells in regions where the photoreceptor cell layer remained relatively intact (G) and many apoptotic cells in regions where the
photoreceptor cells were nearly depleted (arrows in H). Abbreviations: GCL, ganglion cell layer; INL, inner nuclear layer; L, lens; ONL,
outer nuclear layer. Scale bars, 100 mm (A–F); 50 mm (G, H).











47TGFb Inhibits Vascular DevelopmentFIG. 3. Vascular deficiencies in the retina of TGFb1 transgenic mice. Blood vessels were visualized by ADPase staining in 3-week-old
at-mount retinae (A–C) or 5-day-old retinal cups (D, E). In the 3-week-old wild-type retina, major and micro-vessels were well organized
nd extend to the peripheral retina (A). In the retina of 3-week-old OVE917 mice, a deficiency of microvessels was apparent, especially in
he peripheral regions (B). Vasculature was more severely affected in the retina of 3-week-old OVE920A mice (C). In 5-day-old wild-type
etinal cups (D), hyaloid vessels were well organized and evenly distributed. In the 5-day-old retinal cups of OVE920A mice, there are fewer
yaloid vessels with uneven spacing and poor organization (E). Immunofluorescent labeling of 3-week-old wild-type retinal sections using
nti-mouse serum antibodies shows the presence of three layers of blood vessels in the normal retina (F) while in certain regions of
VE920A retinas, blood vessels were absent (G). In these regions, significant loss of retinal cells was observed (compare the retinal
hickness in F to that in G). Abbreviations: GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer. Scale bars, 100 mm.
IG. 4. Reduced hypervascularization in TGFb1 transgenic mice. Mice expressing T-Ag in the lens (A) exhibited tumor-induced
hypervascularization in the iris and hemorrhage in the eye (arrow in A) at 6 weeks of age. In mice co-expressing T-Ag and TGFb1 (B),
ascularization was reduced and no hemorrhage was observed at the same age.























48 Zhao and OverbeekHowever, the roles of TGFb proteins in ocular development
remain unclear.
To investigate the effects of TGFb signaling on ocular
development, we generated transgenic mice expressing a
self-activating form of TGFb1 from a lens-specific aA-
crystallin promoter (Srinivasan et al., 1998). These mice
exhibit anterior subcapsular cataracts, corneal opacities,
and defects in the iris and ciliary body (Srinivasan et al.,
1998). We now report that these transgenic mice also
exhibit a vascular deficiency in the retina and subsequent
retinal degeneration. Transgenic TGFb1 also reduced lens
umor-induced hypervascularization in the iris and inhib-
ted the accumulation of the excessive hyaloid tissue in
GFb2-null embryos. In addition, transgenic TGFb1 stimu-
lated growth of the corneal stroma and reversed the corneal
phenotype in TGFb2-null embryos. These results indicate
hat endogenous and ectopic TGFb proteins negatively
egulate vascular development in the eye and also influence




Generation of the transgenic mice has been previously described
(Srinivasan et al., 1998). Briefly, a 1.5-kb cDNA encoding an active
orm of human TGFb1 (Arrick et al., 1992) was inserted down-
stream of the lens-specific aA-crystallin promoter and upstream of
V40 small t intron and polyadenylation sequences. Transgenic
ice were generated by microinjection of the construct into
ronuclei of one-cell stage FVB/N embryos (Taketo et al., 1991).
Potential transgenic mice were screened by polymerase chain
reaction (PCR) using DNA extracted from mouse tails. The primers
used for PCR are specific to the SV40 sequences (primer A: 59-GTG
AAG GAA CCT TAC TTC TGT GGT G-39; primer B: 59-GTC CTT
GGG GTC TTC TAC CTT TCT C-39). Since FVB/N mice carry an
autosomal recessive mutation causing retinal degeneration (rd)
(Pittler and Baehr, 1991; Bowes et al., 1993), the transgenic mice
were mated with pigmented inbred C57BL/6 or albino outbred ICR
mice to generate offspring for further analysis. To examine whether
ectopic expression of TGFb1 can inhibit tumor-induced hypervas-
cularization, the TGFb1 transgenic mice were mated with trans-
enic mice with lens tumors induced by SV40 T antigen (T-Ag)
Mahon et al., 1987). Mouse genotypes from the cross-breeding
ere determined by PCR using a primer pair specific to the TGFb1
transgene (primer Tb1b: 59-AGC AGC TGT CCA ACA TGA TC-39
plus primer B) and a primer pair specific to T-Ag (primer TAg1:
59-GCT AGG AGT AGC TAT TGA CCA G-39; primer TAg3:
59-GAA GCA AAG CAA TGC CAC TTT G-39). TGFb1 transgenic
ice were also mated with TGFb2 knockout mice (Sanford et al.,
1997; obtained from The Jackson Laboratory) to examine whether
TGFb1 can compensate for the loss of TGFb2 in the eye. TGFb1
transgenic mice were first mated with TGFb21/2 mice to produce
mice that were heterozygous for TGFb2 and also carried the TGFb1
ransgene. These mice were then mated with TGFb21/2 mice.
TGFb2 mutants were genotyped by PCR (primer 1: 59-AAT GTG
CAG GAT AAT TGC TGC-39; primer 2: 59-AAC TCC ATA GAT
ATG GGG ATG C-39) (Sanford et al., 1997). These primers produce
Copyright © 2001 by Academic Press. All right132-bp and 1.3-kb PCR products from the wild-type and the mutant
alleles, respectively.
Histology and in Situ Hybridizations
Mouse embryos or postnatal eyes were fixed in 10% formalin at
room temperature for 24 h and then rinsed in 70% ethanol for 24 h.
The tissues were dehydrated in a series of increasing concentra-
tions of ethanol, cleared in xylene, and embedded in paraffin wax.
Sections (5 mm) were cut on a microtome for hematoxylin/eosin
taining, immunohistochemistry, apoptosis assay, or for in situ
ybridizations. In situ hybridizations were performed to examine
ransgene expression as previously described (Zhao and Overbeek,
999). Anti-sense RNA probes specific for the SV40 sequences,
ouse VEGF, or VEGF receptors (Flt-1 and Flk-1) were synthesized
n the presence of 35S-UTP. After hybridization to tissue sections,
unhybridized probes were removed by washing and RNase treat-
ment. Tissue sections were then dehydrated and coated with Kodak
NTB-2 emulsion for autoradiography. The slides were developed,
stained with hematoxylin, and mounted with a coverslip for
examination of silver grains under dark-field illumination.
ADPase Staining
The vasculature in the retina was visualized by ADPase staining
following previously described procedures (Lutty and McLeod,
1992). Mouse eyes were collected and fixed overnight in 10%
formalin at 4°C. The neural retinae were dissected from the eyes
and washed three times with tap water before being incubated in
the reaction solution for 15 min at 37°C. The reaction solution
contained 0.2 M Tris maleate (pH 7.2), 2 mM lead nitrate, 6 mM
magnesium chloride, and 1 mg/ml ADP. The retinae were next
washed five times in distilled water followed by development of
the reaction product in 2% ammonium sulfide for 1 min. After
washing in distilled water, the retinae were flat-mounted in 50%
glycerol and photographed.
Immunohistochemistry
Tissue sections were incubated with 5% normal goat serum
(NGS) in phosphate-buffered saline (PBS) at room temperature for
15 min to block nonspecific antibody binding. The tissue sections
were then incubated with rabbit anti-mouse serum antibodies
(Sigma, St. Louis) at 4°C overnight. After rinsing with PBS, the
tissue sections were incubated with fluorescein-labeled goat anti-
rabbit IgG (Sigma) at room temperature for 1 h. The slides were
then rinsed with PBS and coverslipped in 50% glycerol in PBS for
examination and photography under blue light illumination.
Assay for Apoptosis
Terminal deoxynucleotidyl transferase-mediated deoxyuridine
triphosphate nick-end labeling (TUNEL) assays were carried out to
detect programmed cell death as previously described (Fromm et
al., 1994). Tissue sections were incubated with terminal deoxynu-
cleotidyl transferase and biotin-16–dUTP. Biotin incorporation
was detected with an avidin–peroxidase complex, followed by
visualization with diaminobenzidine–H2O2. Sections were coun-
terstained with Nuclear Fast Red (Poly Scientific, Bay Shore, NY).
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Transgenic Mice
Lens-specific expression of the TGFb1 transgene was
demonstrated at embryonic day 16 (E16) by in situ hybrid-
izations using a riboprobe specific to the SV40 sequences
(Fig. 1). Family 920A showed the highest levels of transgene
expression (Figs. 1D and 1H). In all transgenic families, the
overall morphology of the retina and the lens appeared
normal during embryonic development, but formation of
the vitreous was delayed (Figs. 1B–1D). In family OVE920A,
the vitreous body never developed in the FVB/N strain and
therefore these mice all had small eyes. When OVE920A
transgenic mice were mated with the outbred strain ICR,
approximately 50% of the transgenic offspring had nearly
normal eye size. Some of the FVB/ICR transgenic mice had
one normal-size eye and one small eye (data not shown). In
embryos from the OVE920A family, there was a significant
increase in the thickness of the corneal stroma (Fig. 1D),
suggesting that TGFb stimulates proliferation and/or mi-
gration of neural crest-derived stromal cells. In other trans-
genic families, changes in the cornea thickness were insig-
nificant (compare Figs. 1B and 1C with Fig. 1A). In all
transgenic families, subcapsular cataracts were observed in
the lens by 3 weeks of age as previously described (Sriniva-
san et al., 1998). In family OVE920A, the subcapsular
cataracts were present in neonatal mice (data not shown),
indicating that the age of onset of the phenotype is corre-
lated with the level of transgene expression.
Retinal Degeneration
Loss of retinal cells was observed in family OVE920A by
2 weeks of age and in families OVE853 and OVE917 by 4
weeks of age. Retinal thickness was significantly reduced in
OVE920A mice by 3 weeks of age (Figs. 2B and 2C). Loss of
photoreceptors was more severe in certain areas (Fig. 2C) of
the retina than others (Fig. 2B). Severe photoreceptor degen-
eration usually occurred in the peripheral retina and was
sometimes associated with loss of pigmentation in the RPE
and/or loss of pigmented choroidal tissues (arrow in Fig.
2C). In family OVE917, the retina was thinner than that of
the wild type at 1 month of age (compare Fig. 2D with 2E).
In 3-month-old OVE917 mice, the thickness of the retina
was significant reduced (Fig. 2F). In general, retinal degen-
eration was more severe in OVE920A mice than in OVE853
or OVE917 mice in all retinal layers at comparable ages. No
apparent loss of pigmentation in the RPE or the choroid was
observed in families other than OVE920A. Since RPE and
choroid were not exposed to the transgenic TGFb1 pro-
duced by the lens, the defects in the RPE and/or choroid in
family OVE920A were presumed to be caused by changes in
biochemistry and/or blood supply in the neural retina
rather than being induced directly by transgenic TGFb1.
To determine whether retinal cells in TGFb1 transgenic
ice died through programmed cell death, TUNEL assays
ere carried out with 3-week-old retinal sections from a
Copyright © 2001 by Academic Press. All rightVE920A mice. No apoptotic cells were detected in regions
here no severe loss of retinal cells was observed (Fig. 2G).
any apoptotic cells were detected in areas of the retina
here significant loss of photoreceptors had occurred
Fig. 2H).
Vascular Deficiency
To determine whether the retinal degeneration was asso-
ciated with vascular defects in the retina, ADPase staining
was carried out to visualize the retinal vasculature in
transgenic mice and their nontransgenic littermates. In
3-week-old wild-type mice (Fig. 3A), the retinal vasculature
was well established and the major and microvessels can be
clearly seen. In the transgenic mice at the same age, retinal
vasculature was compromised (Fig. 3B and 3C). Family
OVE920A showed the most severe vascular deficiency (Fig.
3C). To determine whether vascular development was also
affected at earlier stages, vasculature in the eyecup of
postnatal mice was visualized by ADPase staining. In the
wild-type mice at postnatal day 5 (P5), organized and evenly
spaced hyaloid vessels were observed (Fig. 3D). In the
eyecup of OVE920A mice at P5, there were fewer blood
vessels and they appeared abnormal in size and in distribu-
tion (Fig. 3E). The presence of retinal blood vessels was also
assayed in tissue sections by immunolabeling with anti-
mouse serum antibodies (Sigma). At 3 weeks of age, blood
vessels were clearly identified in wild-type retina (Fig. 3F).
In OVE920A mice, blood vessels were absent in certain
areas of the retina (Fig. 3G). The absence of blood vessels
was always associated with a significant reduction of reti-
nal thickness (compare the retinal thickness in Fig. 3F to
that in Fig. 3G).
Reduction in Tumor-Induced Hypervascularization
To test whether transgenic TGFb1 can have any effect on
neovascularization in the eye, OVE920A mice were mated
with transgenic mice expressing SV40 T-Ag in the lens
driven by the same aA-crystallin promoter (family OVE31)
Mahon et al., 1987). The T-Ag mice develop lens tumors
nd show hypervascularization in the iris (Fig. 4A) and
emorrhage (arrow in Fig. 4A) in the eyes at 6 weeks of age.
hen TGFb1 was co-expressed in the eye, the blood vessels
n the iris were thinner and hemorrhage was not seen at this
ge (Fig. 4B).
Expression of VEGF and Its Receptors
VEGF is known to be a potent angiogenic factor and its
expression can be elevated under hypoxic conditions. One
would expect an increase in VEGF expression in the eye of
transgenic mice due to their vascular deficiency. Alterna-
tively, transgenic TGFb1 might inhibit retinal angiogenesis
by suppressing VEGF expression. We assayed VEGF mRNA
expression by in situ hybridizations. Surprisingly, neither
n increase nor a decrease in VEGF mRNA expression was








50 Zhao and Overbeekobserved in the eye of OVE920A mice compared to the wild
type (data not shown). VEGF transcripts were detected in
the retinal astrocytes at the vitreous surface, in the Mu¨ller
cells in the inner nuclear layer, and in the RPE as previously
reported (Stone and Maslim, 1997). We also examined the
possibility of whether expression of VEGF receptors Flt-1 or
Flk-1 could be affected. In situ hybridization results show
that transgenic TGFb1 had no apparent effect on mRNA
levels of Flt-1 or Flk-1 (data not shown). Transcripts for
Flt-1 and Flk-1 were detected in the endothelial cells of
hyaloid blood vessels around the lens and near the retina.
They were also detected in a subset of choroidal cells
adjacent to the RPE but not RPE itself.
Compensation for TGFb2 Loss by Transgenic
TGFb1
Mice deficient for TGFb1, TGFb2, or TGFb3 have been
FIG. 5. Rescue of the ocular phenotypes in the TGFb2-null emb
section from a TGFb2-null embryo (A) shows stromal cell deficienc
in the vitreous (arrowhead). In the TGFb2-null embryo expressing
the excess hyaloid cells were eliminated (arrowhead). The boxed r
respectively. The vitreous of the TGFb2-null embryo was filled wi
mesenchymal cells (C). The hyaloid vasculature in the TGFb2-nul
of the wild-type mice (D). Abbreviations: L, lens; NR, neural retingenerated by gene targeting, but only the TGFb2-null mice
Copyright © 2001 by Academic Press. All rightxhibit ocular abnormalities (Shull et al., 1992; Kulkarni et
l., 1993; Sanford et al., 1997; Proetzel et al., 1995; Kaarti-
en et al., 1995). Disruption of TGFb2 gene causes perinatal
ethality (Sanford et al., 1997). To test whether transgenic
GFb1 can compensate for the loss of TGFb2 function in
he eye, OVE920A mice were bred onto the TGFb2-null
background. In the eyes of TGFb2-null embryos, the cornea
is deficient in stromal cells (arrow in Fig. 5A). In the
vitreous, there is excessive and disorganized hyaloid tissue
(Fig. 5A), which appears to consist of blood vessels contain-
ing blood cells, undifferentiated angioblasts, and perhaps
other mesenchymal cells (Fig. 5C). In the TGFb2-null
embryo that expressed transgenic TGFb1, the corneal phe-
notype was reversed (arrow in Fig. 5B). The corneal thick-
ness increased significantly and was even slightly greater
than the wild type (see Fig. 1). In the vitreous, the hyper-
plasia of the hyaloid tissue was eliminated (Figs. 5B and
by transgenic TGFb1. Hematoxylin/eosin staining of an E16 eye
the cornea (arrow) and the excessive accumulation of hyaloid cells
genic TGFb1 (B), the corneal phenotype was reversed (arrow) and
s in (A) and (B) are shown at higher magnification in (C) and (D),
isorganized mixture of red blood cells, endothelial cells and other
bryo expressing the TGFb1 transgene more closely resembles that





l em5D). These results demonstrate that the ocular phenotypes































51TGFb Inhibits Vascular Developmentcaused by loss of TGFb2 can be, for the most part, rescued
y lens-specific expression of the homologous TGFb1 pro-
tein.
DISCUSSION
TGFb has been shown to have angiogenic or anti-
ngiogenic activities in animal models (Pepper, 1997). The
resent study demonstrates that ectopic TGFb1 expression
can inhibit ocular vascular development and supports the
notion that TGFb is a negative regulator of angiogenesis in
ivo. In most of the experiments showing an angiogenic
ffect of the TGFb protein, marked inflammatory cell
infiltration was observed (Roberts et al., 1986; Sprugel et
al., 1987; Rubbia-Brandt et al., 1991; Frank et al., 1994;
Yang and Moses, 1990; Phillips et al., 1992, 1993; Fajardo et
al., 1996). In these cases, angiogenesis is likely stimulated
by VEGF and other angiogenic factors released by the
inflammatory cells and, therefore, a secondary effect. In
cases where inflammatory reactions were not observed,
TGFb did not induce angiogenesis (Dong et al., 1996;
Passaniti et al., 1992; Nabel et al., 1993; Jhappan et al.,
993; Pierce et al., 1993; Lee et al., 1995; Sanderson et al.,
1995; Wyss-Coray et al., 1995; Sellheyer et al., 1995; Zhou
t al., 1996). In vitro studies have shown that TGFb can
inhibit proliferation of vascular endothelial cells and
smooth muscle cells (SMCs) (Orlidge and D’Amore, 1987;
Sato et al., 1990; Beck and D’Amore, 1997). Since vascular
cells but not retinal neurons express both type I and type II
TGFb receptors (Srinivasan et al., 1998; Obata et al., 1999),
it is likely that TGFb proteins modulate retinal vascular
evelopment by directly acting upon vascular endothelial
ells and/or pericytes. TGFb may promote differentiation
and physical interactions of endothelial cells and pericytes
which leads to maturation of blood vessels. Gene-targeting
studies have shown that in embryos lacking TGFb1 or type
I TGFb receptor, contacts between vascular endothelial
cells either do not form or are disrupted in the yolk sac
(Dickson et al., 1995; Oshima et al., 1996). The TGFb
binding protein endoglin has been demonstrated to regulate
differentiation of smooth muscle cells and endothelial
remodeling (Li et al., 1999).
Mesenchymal cell accumulation in the vitreous of
TGFb2-null embryos was previously reported (Sanford et
l., 1997). The authors hypothesized that the excessive
umber of cells in the vitreous resulted from failure in
limination of the vascular tunic and suggested that TGFb2
plays a role in ocular tissue remodeling. However, our
transgenic and cross-breeding data suggest that TGFb sig-
aling controls the proper growth and maturation of ocular
asculature in a dosage-sensitive manner. Although endog-
nous TGFb1 is expressed in rodent eyes in a pattern
imilar to TGFb2 (Srinivasan et al., 1998; Gordon-Thomson
t al., 1998), it is apparently unable to compensate for the
oss of TGFb2 either because it activates a different signal-
ng pathway or because its dosage is insufficient. We show
Copyright © 2001 by Academic Press. All righthat additional dosage of TGFb1 derived from the transgene
an rescue the ocular phenotypes in TGFb2-null embryos,
ndicating that these two family members must be capable
f stimulating similar responses in the ocular tissues and
hat an appropriate level of TGFb signaling is critical for
normal development of ocular vasculature.
TGFb proteins have been implicated in ocular diseases. It
as been reported that decreases in levels of active TGFb
protein in the vitreous were associated with active prolif-
erative diabetic retinopathy and hypoxic angiogenesis in
patients (Spranger et al., 1999). This is consistent with our
finding that TGFb proteins can inhibit ocular angiogenesis.
It is also known that the vitreous in patients with prolif-
erative vitreoretinopathy (Gaudric et al., 1990; Kon et al.,
1999) or primary open-angle glaucoma (Tripathi et al., 1994)
contains abnormally high levels of TGFb protein. It is not
et known whether the high levels of TGFb are a cause or
consequence of these diseases.
In summary, our present study demonstrates that TGFb
signaling plays an important role in regulation of ocular
vascular development. Our results show that either over-
production or underproduction of TGFb proteins causes
ocular abnormalities, indicating that the expression and/or
activation of these proteins must be tightly controlled
during normal development. Since elevated TGFb signaling
oes not appear to affect expression of VEGF and its
eceptors Flt-1 and Flk-1, it will be interesting to find out
ow VEGF and TGFb signaling pathways interact at mo-
lecular levels in regulation of vascular development.
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